Skip to main content

Table 1 Characteristics of 387 patients with severe rhabdomyolysis

From: Short- and long-term renal outcomes following severe rhabdomyolysis: a French multicenter retrospective study of 387 patients

 Population, n = 387Acute kidney injury stage 2–3p value
Yes, n = 229 (%)No, n = 158 (73.4%)
Age (years)48.8 (34.5–62.5)50 ± 1847 ± 210.09
Female gender (n, %)115 (29.7)68 (29.7)47 (29.7)1.00
Past medical history
 Drugs abuse (n, %)75 (19.3)21 (9.2)9 (5.7)0.25
 Diabetes mellitus (n, %)30 (7.7)29 (12.7)10 (6.3)0.06
 Cirrhosis (n, %)27 (6.9)4 (1.7)1 (0.6)0.65
 RAAS blocking agents (n, %)5 (1.2)44 (19.2)20 (12.6)0.10
 Cortisone (n, %)64 (16.5)8 (3.5)1 (0.6)0.09
 Diuretics (n, %)9 (2.3)20 (8.7)7 (4.4)0.14
Characteristics at the admission
 Creatine phosphokinase (×103; IU/L)8167 [3173–19,604]31.7 ± 99.710.9 ± 15.40.0002
 Myoglobin (×103; ng/mL)8433 [3272–21,715]24.6 ± 41.310.1 ± 18.9< 0.0001
 Serum phosphorus (mmol/L)1.27 [0.89–1.69]1.58 ± 0.81.1 ± 0.52< 0.0001
 Serum calcium (mmol/L)2.07 [1.83–2.22]2.01 ± 0.32.08 ± 0.30.02
 Serum potassium (mmol/L)4.4 [3.9–5.3]4.9 ± 1.24.2 ± 0.8< 0.0001
 Serum bicarbonate (mmol/L)21 [17–24]19.3 ± 5.42.2 ± 4.8< 0.0001
 Arterial lactates (mmol/L)2.9 [1.7–4.9]4.5 ± 3.93.3 ± 3.20.001
 Bilirubin (mmol/L)10 [6.4–16.3]75 ± 2065 ± 220.51
 Prothrombin time (%)87 (22.4)201 ± 91205 ± 90< 0.0001
 Platelet count (G/L)194 [137–255]12.6 ± 3.114.6 ± 150.39
 Hemoglobin (g/dL)12.9 [11–14.7]  0.24
Causes of rhabdomyolysis0.03
 Crush syndrome (n, %)108 (27.9)52 (22.8)56 (35.4) 
 Vascular ischemia (n, %)71 (18.3)42 (18.3)18 (11.4) 
 Status epilepticus (n, %)15 (3.9)7 (3)8 (5) 
 Immobilization (n, %)131 (33.9)83 (36.2)48 (30.3) 
 Malignant hyperthermia (n, %)7 (1.8)6 (2.7)1 (0.7) 
 Other (n, %)66 (17)39 (17)27 (17.2) 
Life-sustaining treatments at day 1
 Vasoactive drugs (n, %)185 (47.8)133 (58)52 (32.9)< 0.0001
 Mechanical ventilation (n, %)229 (59.1)155 (67.7)74 (46.8)< 0.0001
  1. RAAS renin–angiotensin–aldosterone system